Status:
UNKNOWN
Transdermal Lidocaine Administration Prior to Insertion Levonorgestrel-releasing Intrauterine System
Lead Sponsor:
Aswan University Hospital
Conditions:
IUCD Complication
Eligibility:
FEMALE
18-45 years
Phase:
NA
Brief Summary
aims to investigate the effectiveness of Transdermal lidocaine patch for Pain Control During Levonorgestrel Releasing Intrauterine System Insertion in Women Delivered Only by Elective Cesarean Section
Detailed Description
Long-acting reversible contraception methods are highly effective methods for reduction of the unplanned pregnancy rate worldwide. The intrauterine device is a single procedure that provides reliable,...
Eligibility Criteria
Inclusion
- Non-pregnant women
- Women that did not receive any analgesics or Dinoprostone in the 24 hours prior to insertion
- Women who delivered only by cesarean section
Exclusion
- Women with any uterine abnormalities as congenital anomalies, endometrial lesions, adenomyosis, fibroids.
- Those with a Category 3 or 4 conditions for intrauterine device insertion according to the WHO Medical Eligibility Criteria for contraceptive use
- Allergy to lidocaine
- Women refuse to participate in the study
Key Trial Info
Start Date :
September 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2021
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04517890
Start Date
September 1 2020
End Date
September 1 2021
Last Update
September 21 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Aswan University Hospital
Aswān, Egypt, 81528